FY2017 Earnings Forecast for Collegium Pharmaceutical, Inc. Issued By William Blair (COLL)

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Stock analysts at William Blair boosted their FY2017 earnings per share estimates for Collegium Pharmaceutical in a note issued to investors on Thursday. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will earn ($2.30) per share for the year, up from their previous estimate of ($2.80). William Blair also issued estimates for Collegium Pharmaceutical’s Q4 2017 earnings at ($0.34) EPS, Q1 2018 earnings at ($0.44) EPS, Q3 2018 earnings at ($0.34) EPS, Q4 2018 earnings at ($0.30) EPS, FY2018 earnings at ($0.99) EPS and FY2019 earnings at $0.22 EPS.



Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The business had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The company’s revenue was up 2814.6% on a year-over-year basis. During the same quarter last year, the firm earned ($1.13) EPS.

ILLEGAL ACTIVITY NOTICE: “FY2017 Earnings Forecast for Collegium Pharmaceutical, Inc. Issued By William Blair (COLL)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/15/fy2017-earnings-forecast-for-collegium-pharmaceutical-inc-issued-by-william-blair-coll.html.

A number of other equities research analysts have also issued reports on COLL. Piper Jaffray Companies set a $14.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, July 25th. BidaskClub cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. HC Wainwright began coverage on shares of Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a “buy” rating and a $21.00 target price for the company. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a research report on Thursday, September 21st. Two research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.33.

Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at $14.16 on Monday. Collegium Pharmaceutical has a twelve month low of $7.37 and a twelve month high of $17.73.

Several large investors have recently bought and sold shares of COLL. Nationwide Fund Advisors lifted its position in shares of Collegium Pharmaceutical by 16.4% in the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 1,422 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Collegium Pharmaceutical by 6.1% in the 1st quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after purchasing an additional 3,775 shares during the period. American International Group Inc. lifted its position in shares of Collegium Pharmaceutical by 27.8% in the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after purchasing an additional 2,163 shares during the period. Vanguard Group Inc. lifted its position in shares of Collegium Pharmaceutical by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock worth $8,113,000 after purchasing an additional 58,398 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Collegium Pharmaceutical by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 146,568 shares of the specialty pharmaceutical company’s stock worth $1,474,000 after purchasing an additional 4,866 shares during the period. 83.96% of the stock is owned by hedge funds and other institutional investors.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply